236 related articles for article (PubMed ID: 33476575)
21. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
[TBL] [Abstract][Full Text] [Related]
22. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
[TBL] [Abstract][Full Text] [Related]
23. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
[TBL] [Abstract][Full Text] [Related]
24. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
[TBL] [Abstract][Full Text] [Related]
25. Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis.
Murugesan A; Lassalle-Claux G; Hogan L; Vaillancourt E; Selka A; Luiker K; Kim MJ; Touaibia M; Reiman T
J Nat Prod; 2020 Dec; 83(12):3526-3535. PubMed ID: 33210536
[TBL] [Abstract][Full Text] [Related]
26. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.
Du L; Liu W; Pichiorri F; Rosen ST
Cancer Gene Ther; 2023 Apr; 30(4):567-574. PubMed ID: 35338347
[TBL] [Abstract][Full Text] [Related]
27. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
28. TIPE2, a negative regulator of TLR signaling, regulates p27 through IRF4-induced signaling.
Peng Y; Zhao Q; Zhang H; Han B; Liu S; Han M; Liu S
Oncol Rep; 2016 Apr; 35(4):2480-6. PubMed ID: 26781452
[TBL] [Abstract][Full Text] [Related]
29. An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1
Xu S; Zhou T; Doh HM; Trinh KR; Catapang A; Lee JT; Braas D; Bayley NA; Yamada RE; Vasuthasawat A; Sasine JP; Timmerman JM; Larson SM; Kim Y; MacLeod AR; Morrison SL; Herschman HR
Cancer Res; 2019 May; 79(10):2748-2760. PubMed ID: 30885978
[TBL] [Abstract][Full Text] [Related]
30. The dynamic functions of IRF4 in B cell malignancies.
Maffei R; Fiorcari S; Atene CG; Martinelli S; Mesini N; Pilato F; Lagreca I; Barozzi P; Riva G; Nasillo V; Paolini A; Forghieri F; Potenza L; Trenti T; Tagliafico E; Luppi M; Marasca R
Clin Exp Med; 2023 Aug; 23(4):1171-1180. PubMed ID: 36495369
[TBL] [Abstract][Full Text] [Related]
31. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
32. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
33. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma.
Kudo C; Yamakoshi H; Sato A; Ohori H; Ishioka C; Iwabuchi Y; Shibata H
Anticancer Res; 2011 Nov; 31(11):3719-26. PubMed ID: 22110192
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
Ryu D; Kim HJ; Joung JG; Lee HO; Bae JS; Kim SJ; Kim H; Park WY; Kim K
Oncotarget; 2016 Jul; 7(30):47127-47133. PubMed ID: 27223072
[TBL] [Abstract][Full Text] [Related]
35. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
36. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
[TBL] [Abstract][Full Text] [Related]
37. The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.
Banerjee S; Lu J; Cai Q; Saha A; Jha HC; Dzeng RK; Robertson ES
PLoS Pathog; 2013; 9(5):e1003314. PubMed ID: 23658517
[TBL] [Abstract][Full Text] [Related]
38. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication.
Lee HR; Doğanay S; Chung B; Toth Z; Brulois K; Lee S; Kanketayeva Z; Feng P; Ha T; Jung JU
J Virol; 2014 Feb; 88(4):2183-94. PubMed ID: 24335298
[TBL] [Abstract][Full Text] [Related]
39. Implication of IRF4 aberrant gene expression in the acute leukemias of childhood.
Adamaki M; Lambrou GI; Athanasiadou A; Tzanoudaki M; Vlahopoulos S; Moschovi M
PLoS One; 2013; 8(8):e72326. PubMed ID: 23977280
[TBL] [Abstract][Full Text] [Related]
40. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
Weilemann A; Grau M; Erdmann T; Merkel O; Sobhiafshar U; Anagnostopoulos I; Hummel M; Siegert A; Hayford C; Madle H; Wollert-Wulf B; Fichtner I; Dörken B; Dirnhofer S; Mathas S; Janz M; Emre NC; Rosenwald A; Ott G; Lenz P; Tzankov A; Lenz G
Blood; 2015 Jan; 125(1):124-32. PubMed ID: 25359993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
